$3.74
0.020.54%
Last update: Nov 11, 4:00 PM
Fulcrum Therapeutics Inc (FULC) Stock Price, Quote, News & History
FULCNASDAQ
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.
You can purchase shares of Fulcrum Therapeutics (NASDAQ:FULC) through any online brokerage.
Other companies in Fulcrum Therapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Fulcrum Therapeutics has a consensus price target of $8.00.
The stock price for Fulcrum Therapeutics (NASDAQ: FULC) is $3.74 last updated November 11, 2026 at 4:00 PM EST.
There are no upcoming dividends for Fulcrum Therapeutics.
Fulcrum Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Fulcrum Therapeutics.
Fulcrum Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF)...
